TY - JOUR
T1 - NANETS/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy
AU - Hope, Thomas A.
AU - Bodei, Lisa
AU - Chan, Jennifer A.
AU - El-Haddad, Ghassan
AU - Fidelman, Nicholas
AU - Kunz, Pamela L.
AU - Mailman, Josh
AU - Menda, Yusuf
AU - Metz, David C.
AU - Mittra, Erik S.
AU - Pryma, Daniel A.
AU - Reidy-Lagunes, Diane L.
AU - Singh, Simron
AU - Strosberg, Jonathan R.
N1 - Publisher Copyright:
COPYRIGHT © 2020 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2020/2
Y1 - 2020/2
N2 - With the growing use of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), there are many unanswered questions regarding patient selection. In this document, we review the literature on the use of 177Lu-DOTATATE in neuroendocrine tumors (NETs) of different primary origin, discuss issues of controversy, and review potential contraindications to treatment. The present consensus statement was developed collaboratively by the North American Neuroendocrine Tumor Society (NANETS) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). NANETS is a multidisciplinary professional society of neuroendocrine specialists in North America that was founded in 2005. NANETS’ mission is to improve NET disease management through increased research and educational opportunities. NANETS is committed to a multidisciplinary approach and consists of doctors and scientists involved in different specialties of NETs. SNMMI is an international scientific and professional organization founded in 1954 to promote the science, technology and practical application of nuclear medicine. In addition to publishing journals, newsletters, and books, the SNMMI also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine practitioners and to promote new advances in the science of nuclear medicine.
AB - With the growing use of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), there are many unanswered questions regarding patient selection. In this document, we review the literature on the use of 177Lu-DOTATATE in neuroendocrine tumors (NETs) of different primary origin, discuss issues of controversy, and review potential contraindications to treatment. The present consensus statement was developed collaboratively by the North American Neuroendocrine Tumor Society (NANETS) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). NANETS is a multidisciplinary professional society of neuroendocrine specialists in North America that was founded in 2005. NANETS’ mission is to improve NET disease management through increased research and educational opportunities. NANETS is committed to a multidisciplinary approach and consists of doctors and scientists involved in different specialties of NETs. SNMMI is an international scientific and professional organization founded in 1954 to promote the science, technology and practical application of nuclear medicine. In addition to publishing journals, newsletters, and books, the SNMMI also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine practitioners and to promote new advances in the science of nuclear medicine.
UR - http://www.scopus.com/inward/record.url?scp=85078920014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078920014&partnerID=8YFLogxK
U2 - 10.2967/JNUMED.119.240911
DO - 10.2967/JNUMED.119.240911
M3 - Article
C2 - 32015164
AN - SCOPUS:85078920014
SN - 0161-5505
VL - 61
SP - 222
EP - 227
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 2
ER -